To date, the RNAi targeting VEGF-basedtherapeutics in combination with chemotherapeuticagents have been found to enhance the therapeuticefficacy of an anti-tumor drug to eradicatecolorectal cancer cells, bladder cancer cells, breastcancer cells and myeloma cells (21-24). Here, VEGFA is linked to plasma cell myeloma.